ro 46-2005 has been researched along with tbc-11251 in 1 studies
| Studies (ro 46-2005) | Trials (ro 46-2005) | Recent Studies (post-2010) (ro 46-2005) | Studies (tbc-11251) | Trials (tbc-11251) | Recent Studies (post-2010) (tbc-11251) |
|---|---|---|---|---|---|
| 26 | 0 | 1 | 167 | 32 | 58 |
| Protein | Taxonomy | ro 46-2005 (IC50) | tbc-11251 (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Homo sapiens (human) | 4.9049 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0014 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolli, MH; Boss, C; Gatfield, J | 1 |
1 review(s) available for ro 46-2005 and tbc-11251
| Article | Year |
|---|---|
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
Topics: Bosentan; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Humans; Molecular Structure; Pyrimidines; Receptors, Endothelin; Structure-Activity Relationship; Sulfonamides | 2016 |